VIRAX BIOLABS GROUP LTD
VRAXNASDAQ🏆 #5228 by market capUS Equity
$1.18▲ $0.00 (+0.00%)
Market closed · at closeTrack VRAX
Get earnings, price moves & breaking news on Telegram
24h▲ 0.0%
7d▲ 1.7%
14d▼ 28.5%
30d▼ 46.4%
ytd▼ 87.8%
1y▼ 92.1%
🏦Market Cap
$2M
Small Cap
📈Revenue Growth (YoY)
96.2%
High Growth
📊Gross Margin
-1480.5%
Thin
💵FCF Margin
-56607.7%
Thin
⚖️P/S Ratio
115.0x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $1.18 – $1.18
- 52-Week Range
- $1.14 – $21.75
- Volume (shares)
- 328
- Avg Volume (shares)
- —
- Shares Outstanding
- 1.3M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- $12,423
- Last Q Revenue
- $12,423
- P/E Ratio
- -0.0
- P/S Ratio
- 115.0x
- EPS (TTM)
- $-18.52
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +108.7%
VIRAX BIOLABS GROUP LTD
VRAXFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$12K▲ +96.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
61.9%▼ −107.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$6M▲ +3.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$5M▼ −5.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
398K▲ +108.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$6M▲ +$3M YoY
StockOtter · stockotter.spaceAbout VIRAX BIOLABS GROUP LTD
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.